The impact of the cord blood methylome on early-onset pediatric atopic dermatitis
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Project summary: With the growing prevalence of pediatric atopic dermatitis (AD) and subsequent food allergy, asthma and allergic rhinitis, there is an unmet need to identify early biomarkers to allow early disease-preventative interventions. Recent studies emphasize the heritable and environmental components of early-onset AD. DNA methylation (DNAm), a regulator of gene expression highly reactive to environmental exposures, is one potential mechanistic biomarker that that may work along the causal pathway. In our population birth cohort, the Wayne County, Health, Environment, Allergy and Asthma Longitudinal Study (WHEALS), we identified differential cord-blood DNAm in children with early-onset AD compared to those without. Furthermore, we created a cord-blood poly-CpG score that differentiates those with early-onset AD, with a cross-validated AUC of 0.937. We aim to further investigate the connection between cord-blood DNAm and newborn blood spot DNAm, and early-onset AD in the context of established germline genetic and environmental AD risk factors. Using a rigorous framework, we will achieve this objective through the following Specific Aims: Aim 1: To identify and validate cord blood DNAm associated with early-onset AD in the context of in- utero environmental factors. We will use WGBS to identify and validate cord blood DNAm variation associated with early-onset AD in five birth cohorts spanning urban, suburban, and rural environments for early-onset AD and whether known AD-associated prenatal factors lie upstream in the causal pathway. We will also investigate whether methylation-based gestational age is associated with early-onset AD risk and the impact of the prenatal environment on this relationship. Leveraging our Henry Ford Health Eczema and Primary Care Clinics, we will also determine whether the cord-blood signatures for early-onset AD translate to newborn blood spot DNAm. Aim 2: To determine whether cord blood DNAm causally impacts risk of early-onset AD using Mendelian randomization. First, we will determine which of the 101 multi-ethnic GWAS established risk variants are cord blood methylation quantitative trait loci (mQTL) using an epigenome-wide analysis approach. Second, for those risk variants that are also mQTL, we will use these variants as instrumental variables to assess the causal relationship of the CpG sites with early-onset AD using one-sample Mendelian randomization methods. Aim 3: To determine the individual and joint contributions of DNAm, genetic, and prenatal environment scores to the prediction of early-onset AD. We will develop and validate poly-prenatal environmental risk scores (PERS) and poly-CpG risk scores (PCRS) for early-onset AD, and along with an existing polygenic risk score (PGRS) for AD, evaluate their separate and joint impact on early-onset AD prediction.
Grant Summary
The impact of the cord blood methylome on early-onset pediatric atopic dermatitis is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $784K for university, nonprofit, healthcare org. Applications are due 2031-05-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $784K
2031-05-31
- 1Confirm your organization is eligible for The impact of the cord blood methylome on early-onset pediatric atopic dermatitis from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
The impact of the cord blood methylome on early-onset pediatric atopic dermatitis: Frequently Asked Questions
Who is eligible for the The impact of the cord blood methylome on early-onset pediatric atopic dermatitis?
The impact of the cord blood methylome on early-onset pediatric atopic dermatitis is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the The impact of the cord blood methylome on early-onset pediatric atopic dermatitis provide?
The impact of the cord blood methylome on early-onset pediatric atopic dermatitis provides up to $784K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the The impact of the cord blood methylome on early-onset pediatric atopic dermatitis deadline?
Applications for The impact of the cord blood methylome on early-onset pediatric atopic dermatitis are due 2031-05-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the The impact of the cord blood methylome on early-onset pediatric atopic dermatitis?
To apply for The impact of the cord blood methylome on early-onset pediatric atopic dermatitis, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.